| 1. |
- Kabir, Md. Tanvir, et al.
(författare)
-
Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers
- 2021
-
Ingår i: Biomolecules. - : MDPI AG. - 2218-273X. ; 11:3
-
Forskningsöversikt (refereegranskat)abstract
- Cancer is a major burden of disease globally. Each year, tens of millions of people are diagnosed with cancer worldwide, and more than half of the patients eventually die from it. Significant advances have been noticed in cancer treatment, but the mortality and incidence rates of cancers are still high. Thus, there is a growing research interest in developing more effective and less toxic cancer treatment approaches. Curcumin (CUR), the major active component of turmeric (Curcuma longa L.), has gained great research interest as an antioxidant, anticancer, and anti-inflammatory agent. This natural compound shows its anticancer effect through several pathways including interfering with multiple cellular mechanisms and inhibiting/inducing the generation of multiple cytokines, enzymes, or growth factors including IκB kinase β (IκKβ), tumor necrosis factor-alpha (TNF-α), signal transducer, and activator of transcription 3 (STAT3), cyclooxygenase II (COX-2), protein kinase D1 (PKD1), nuclear factor-kappa B (NF-κB), epidermal growth factor, and mitogen-activated protein kinase (MAPK). Interestingly, the anticancer activity of CUR has been limited primarily due to its poor water solubility, which can lead to low chemical stability, low oral bioavailability, and low cellular uptake. Delivering drugs at a controlled rate, slow delivery, and targeted delivery are other very attractive methods and have been pursued vigorously. Multiple CUR nanoformulations have also been developed so far to ameliorate solubility and bioavailability of CUR and to provide protection to CUR against hydrolysis inactivation. In this review, we have summarized the anticancer activity of CUR against several cancers, for example, gastrointestinal, head and neck, brain, pancreatic, colorectal, breast, and prostate cancers. In addition, we have also focused on the findings obtained from multiple experimental and clinical studies regarding the anticancer effect of CUR in animal models, human subjects, and cancer cell lines.
|
|
| 2. |
- Tuli, Hardeep Singh, et al.
(författare)
-
Natural flavonoids exhibit potent anticancer activity by targeting microRNAs in cancer : A signature step hinting towards clinical perfection
- 2023
-
Ingår i: Translational Oncology. - : Elsevier BV. - 1936-5233. ; 27
-
Tidskriftsartikel (refereegranskat)abstract
- Cancer prevalence and its rate of incidence are constantly rising since the past few decades. Owing to the toxicity of present-day antineoplastic drugs, it is imperative to explore safer and more effective molecules to combat and/or prevent this dreaded disease. Flavonoids, a class of polyphenols, have exhibited multifaceted implications against several diseases including cancer, without showing significant toxicity towards the normal cells. Shredded pieces of evidence suggest that flavonoids can enhance drug sensitivity and suppress proliferation, metastasis, and angiogenesis of cancer cells by modulating several oncogenic or oncosuppressor microRNAs (miRNAs, miRs). They play pivotal roles in regulation of various biological and pathological processes, including various cancers. In the present review, the structure, chemistry and miR targeting efficacy of quercetin, luteolin, silibinin, genistein, epigallocatechin gallate, and cyanidin against several cancer types are comprehensively discussed. miRs are considered as next-generation medicine of recent times, and their targeting by naturally occurring flavonoids in cancer cells could be deemed as a signature step. We anticipate that our compilations related to miRNA-mediated regulation of cancer cells by flavonoids might catapult the clinical investigations and affirmation in the future.
|
|
| 3. |
- Uddin, Md Sahab, et al.
(författare)
-
Revisiting the Amyloid Cascade Hypothesis : From Anti-A beta Therapeutics to Auspicious New Ways for Alzheimer's Disease
- 2020
-
Ingår i: International Journal of Molecular Sciences. - : MDPI. - 1661-6596 .- 1422-0067. ; 21:16
-
Forskningsöversikt (refereegranskat)abstract
- Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder related to age, characterized by the cerebral deposition of fibrils, which are made from the amyloid-beta (A beta), a peptide of 40-42 amino acids. The conversion of A beta into neurotoxic oligomeric, fibrillar, and protofibrillar assemblies is supposed to be the main pathological event in AD. After A beta accumulation, the clinical symptoms fall out predominantly due to the deficient brain clearance of the peptide. For several years, researchers have attempted to decline the A beta monomer, oligomer, and aggregate levels, as well as plaques, employing agents that facilitate the reduction of A beta and antagonize A beta aggregation, or raise A beta clearance from brain. Unluckily, broad clinical trials with mild to moderate AD participants have shown that these approaches were unsuccessful. Several clinical trials are running involving patients whose disease is at an early stage, but the preliminary outcomes are not clinically impressive. Many studies have been conducted against oligomers of A beta which are the utmost neurotoxic molecular species. Trials with monoclonal antibodies directed against A beta oligomers have exhibited exciting findings. Nevertheless, A beta oligomers maintain equivalent states in both monomeric and aggregation forms; so, previously administered drugs that precisely decrease A beta monomer or A beta plaques ought to have displayed valuable clinical benefits. In this article, A beta-based therapeutic strategies are discussed and several promising new ways to fight against AD are appraised.
|
|
